Key result
Troponins, BNP, H-FABP, and GDF-15 help evaluate myocardial injury and RV dysfunction in PE.
Why the study?
Right ventricular dysfunction is a key determinant of prognosis and management in pulmonary thromboembolism, warranting comprehensive biomarker evaluation alongside imaging and hemodynamic assessments.
A comprehensive evaluation using multiple biomarkers can improve the early detection and risk stratification of right ventricular dysfunction in patients with pulmonary embolism.
Pulmonary thromboembolism (PE) is a life-threatening condition that often leads to right ventricular (RV) dysfunction, a key determinant of prognosis and clinical management. Biomarkers play a crucial role in the early detection and risk stratification of RV dysfunction in PE, complementing imaging and hemodynamic assessments. Cardiac troponins, B-type natriuretic peptides, and novel biomarkers, such as heart-type fatty acid-binding protein (H-FABP) and growth differentiation factor-15 (GDF-15), provide valuable insights into myocardial injury, overload, and stress. This article explores the clinical possible significance of these biomarkers, their predictive value, and their potential to guide therapeutic strategies in patients with PE. Understanding the role of biomarkers in RV dysfunction assessment may improve patient outcomes focusing on early intervention and personalized treatment approaches.
No takes yet. Share an insight, caveat, or question.
Cucută et al. (2025) conducted a review in Pulmonary thromboembolism. Biomarkers (Cardiac troponins, B-type natriuretic peptides, H-FABP, GDF-15) was evaluated. Cardiac troponins, B-type natriuretic peptides, H-FABP, and GDF-15 provide valuable insights into myocardial injury and stress for evaluating right ventricular dysfunction in pulmonary embolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: